Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
:QURE
QURE Analyst Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
QURE Stock 12 Month Forecast
Average Price Target
$40.57
▲(189.79% Upside)
| Highest Price Target$70.00 | Average Price Target$40.57 | Lowest Price Target$24.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$14.5
Hold
3.57%
Upside
Reiterated
07/31/25
The overall stock score of 54 reflects the significant financial challenges faced by uniQure, which weigh heavily on the assessment. However, positive sentiment from recent earnings call achievements and corporate events, particularly in advancing clinical programs, provide a balanced outlook. The technical and valuation aspects contribute neutrally, neither strongly enhancing nor detracting from the score.
H.C. Wainwright
$70
Buy
400.00%
Upside
Reiterated
07/30/25
uniQure's Promising Gene Therapy Advances and Strong Financial Position Justify Buy RatingWe assess uniQure using a discounted cash flow (DCF) and sum-of-the-parts (SOTP)-based methodology. We assign a probability of success to with anticipated approval in 2026E. We model a build in revenues tied to uniQure's AAV gene therapy platform in the 2030s, leading to a moderate present value. We employ a 12% discount rate and a terminal multiple of 6.0x. Taken together, these assumptions yield a total firm value of approximately $3.9 billion and price target of $70.
Cantor Fitzgerald
$58→$47
Buy
235.71%
Upside
Reiterated
07/29/25
Leerink Partners
$48
Buy
242.86%
Upside
Reiterated
07/29/25
William Blair
―
Buy
―
Reiterated
07/29/25
TD Cowen
―
Buy
―
Reiterated
07/29/25
Positive Outlook for uniQure's AMT-130 Program Amidst Upcoming 3-Year Data ReleaseWe and QURE remain optimistic that the 3-yr data will continue to show benefit vs. the new external comparator. A pre-BLA meeting and completion of AMT-130 PPQ run are expected in Q4, followed by BLA submission in Q1:26. Early pipeline also progresses. Remain Buy. AMT-130's 3-Year Data Now The Focus Following Alignment With The FDA Focus is on the upcoming 3yr AMT-130 data in September and our recent investor surveys have signaled that the majority are optimistic for a positive readout. The 3yr data will be the first time that the Ph. I/II program will be analyzed using the new finalized SAP and external NH comparator (propensity-score matched external control arm derived from the ENROLL-HD data set) which will provide the basis for the primary efficacy analysis for the BLA package.
Mizuho Securities
―
Hold
―
Reiterated
07/29/25
Chardan Capital
$38→$35
Buy
150.00%
Upside
Reiterated
07/29/25
RBC Capital
$24
Buy
71.43%
Upside
Reiterated
07/29/25
Stifel Nicolaus
$30
Buy
114.29%
Upside
Reiterated
07/07/25
Wells Fargo
$30
Buy
114.29%
Upside
Reiterated
06/02/25
Analysts Offer Insights on Healthcare Companies: Nuvalent (NASDAQ: NUVL), uniQure (NASDAQ: QURE) and UnitedHealth (NYSE: UNH)We note that details of FDA alignment on BLA filing, now backed by meeting minutes, are consistent with prior guidance and represent best-case regulatory path. We also expect 3- yr data in 3Q25 to show benefit in cUHDRS consistent with 2-yr data. QURE announced, following recent Type B meetings and further guidance from FDA, it has reached alignment with FDA on key components of the statistical analysis plan (SAP) and CMC that will support a BLA filing. On program timeline, QURE plans to submit an updated SAP to FDA in 2Q25, initiate a Process Performance Qualification (PPQ) run and report top-line Ph1/2 data per the SAP in 3Q25, hold a pre-BLA meeting w/ FDA in 4Q25, and submit a BLA w/ a request for priority review designation in 1Q26. SAP updates.
Goldman Sachs
$20→$18
Hold
28.57%
Upside
Reiterated
02/28/25
Truist Financial
$9.14
Buy
-34.73%
Downside
Reiterated
12/10/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$14.5
Hold
3.57%
Upside
Reiterated
07/31/25
The overall stock score of 54 reflects the significant financial challenges faced by uniQure, which weigh heavily on the assessment. However, positive sentiment from recent earnings call achievements and corporate events, particularly in advancing clinical programs, provide a balanced outlook. The technical and valuation aspects contribute neutrally, neither strongly enhancing nor detracting from the score.
H.C. Wainwright
$70
Buy
400.00%
Upside
Reiterated
07/30/25
uniQure's Promising Gene Therapy Advances and Strong Financial Position Justify Buy RatingWe assess uniQure using a discounted cash flow (DCF) and sum-of-the-parts (SOTP)-based methodology. We assign a probability of success to with anticipated approval in 2026E. We model a build in revenues tied to uniQure's AAV gene therapy platform in the 2030s, leading to a moderate present value. We employ a 12% discount rate and a terminal multiple of 6.0x. Taken together, these assumptions yield a total firm value of approximately $3.9 billion and price target of $70.
Cantor Fitzgerald
$58→$47
Buy
235.71%
Upside
Reiterated
07/29/25
Leerink Partners
$48
Buy
242.86%
Upside
Reiterated
07/29/25
William Blair
―
Buy
―
Reiterated
07/29/25
TD Cowen
―
Buy
―
Reiterated
07/29/25
Positive Outlook for uniQure's AMT-130 Program Amidst Upcoming 3-Year Data ReleaseWe and QURE remain optimistic that the 3-yr data will continue to show benefit vs. the new external comparator. A pre-BLA meeting and completion of AMT-130 PPQ run are expected in Q4, followed by BLA submission in Q1:26. Early pipeline also progresses. Remain Buy. AMT-130's 3-Year Data Now The Focus Following Alignment With The FDA Focus is on the upcoming 3yr AMT-130 data in September and our recent investor surveys have signaled that the majority are optimistic for a positive readout. The 3yr data will be the first time that the Ph. I/II program will be analyzed using the new finalized SAP and external NH comparator (propensity-score matched external control arm derived from the ENROLL-HD data set) which will provide the basis for the primary efficacy analysis for the BLA package.
Mizuho Securities
―
Hold
―
Reiterated
07/29/25
Chardan Capital
$38→$35
Buy
150.00%
Upside
Reiterated
07/29/25
RBC Capital
$24
Buy
71.43%
Upside
Reiterated
07/29/25
Stifel Nicolaus
$30
Buy
114.29%
Upside
Reiterated
07/07/25
Wells Fargo
$30
Buy
114.29%
Upside
Reiterated
06/02/25
Analysts Offer Insights on Healthcare Companies: Nuvalent (NASDAQ: NUVL), uniQure (NASDAQ: QURE) and UnitedHealth (NYSE: UNH)We note that details of FDA alignment on BLA filing, now backed by meeting minutes, are consistent with prior guidance and represent best-case regulatory path. We also expect 3- yr data in 3Q25 to show benefit in cUHDRS consistent with 2-yr data. QURE announced, following recent Type B meetings and further guidance from FDA, it has reached alignment with FDA on key components of the statistical analysis plan (SAP) and CMC that will support a BLA filing. On program timeline, QURE plans to submit an updated SAP to FDA in 2Q25, initiate a Process Performance Qualification (PPQ) run and report top-line Ph1/2 data per the SAP in 3Q25, hold a pre-BLA meeting w/ FDA in 4Q25, and submit a BLA w/ a request for priority review designation in 1Q26. SAP updates.
Goldman Sachs
$20→$18
Hold
28.57%
Upside
Reiterated
02/28/25
Truist Financial
$9.14
Buy
-34.73%
Downside
Reiterated
12/10/24
Best Analysts Covering uniQure
1 Month
xxx
Success Rate
8/16 ratings generated profit
Average Return
-0.09%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -0.09% per trade.
3 Months
xxx
Success Rate
8/16 ratings generated profit
Average Return
+8.92%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +8.92% per trade.
1 Year
Success Rate
10/16 ratings generated profit
Average Return
+19.66%
reiterated a buy rating 11 days ago
Copying Joseph Thome's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +19.66% per trade.
2 Years
xxx
Success Rate
12/19 ratings generated profit
Average Return
+39.02%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 63.16% of your transactions generating a profit, with an average return of +39.02% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
QURE Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
8
11
17
22
23
Buy
8
7
7
7
8
Hold
6
5
8
5
14
Sell
2
3
3
2
1
Strong Sell
0
0
0
0
0
total
24
26
35
36
46
Each month's total comprises the sum of three months' worth of ratings.
QURE Financial Forecast
QURE Stock Forecast FAQ
What is QURE’s average 12-month price target, according to analysts?
Based on analyst ratings, uniQure N.V.’s 12-month average price target is 40.57.
What is QURE’s upside potential, based on the analysts’ average price target?
uniQure N.V. has 189.79% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is QURE a Buy, Sell or Hold?
uniQure N.V. has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
What is uniQure N.V.’s price target?
The average price target for uniQure N.V. is 40.57. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $70.00 ,the lowest forecast is $24.00. The average price target represents 189.79% Increase from the current price of $14.
The highest analyst price target is $70.00 ,the lowest forecast is $24.00. The average price target represents 189.79% Increase from the current price of $14.
What do analysts say about uniQure N.V.?
uniQure N.V.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of QURE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.